Tag: NCT02574455

Home / NCT02574455

Categories

Sacituzumab govitecan receives FDA approval for triple-negative breast cancer

August 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) gained regular FDA clearance for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who ha...
nct02574455

Scan the code